In a bipartisan spending agreement that was largely negotiated behind closed doors, Congress included a policy change with ...

This contributor column discusses a recent study that shows the 340B Program’s explosive growth is overwhelmingly due to utilization increases, not price. Payers have struggled with the increasing ...

The federal 340B Drug Pricing Program, which requires pharmaceutical manufacturers participating in Medicaid to sell outpatient drugs at discounted prices to healthcare organizations that care for ...

A federal court recently blocked the Trump administration from moving forward with a proposed pilot program that could have ...

That landmark legislation was an example of how Massachusetts has always looked out for vulnerable patients. But even with ...

If New York legislators have questions about the efficacy of the 340B Drug Pricing Program, they should look closely at a ...

The 340B Drug Pricing Program allows certain medical facilities to buy drugs at a discount to support care for low-income patients. Rhode Island's new law, Chapter 288, prevents drug makers from ...

When the 340B drug pricing program was established in 1992, Congress intended for the program to help low-income and uninsured patients with their prescription drugs. The pharmaceutical companies ...

The Patient Protection and Affordable Care Act is expected to bring significant change to the healthcare industry, including the expansion of the Public Health Service Act Section 340B Program.

The pilot is a significant departure from the current model, which gives hospitals upfront discounts for some drugs. The program has proved a flash point between drugmakers and providers, as ...